ALSO NOTED: Dusa, River's Edge settle patent claims; Abaxis appoints new operating VP;

> Dermatological drug maker Dusa Pharmaceuticals has settled a patent-infringement claim with River's Edge Pharmaceuticals, which has been selling a copycat form of Dusa's Nicomide acne med. Report

> Abaxis, which makes portable blood-analysis devices, has hired a new vice president of operations, Donald P. Wood. Report

> Indian regulators who've been cracking down on price-controlled drugs found that more than half the products it sampled were overpriced or had no government-approved pricing. Report

> After five years in partnership with Roche, Kosan Biosciences says it will seek a new partner for its experimental cancer therapy epothilone. Report

> Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their bladder drug vinflunine. Report

> With sales of Aranesp and Epogen on the decline, biotech giant Amgen is feeling the impact right where it hurts the most: The bottom line. Report

And Finally... The saga of drug-resistant staph continues--in Fido and Muffin. Vets say cases of MRSA infections in animals are on the rise, too. Report